TAUNS Laboratories, Inc.
GENEX, Inc.
Announcement of Strategic Capital and Business Alliance
between TAUNS Laboratories, Inc. and GENEX, Inc.
SHIZUOKA and TOKYO, November 30, 2023 - TAUNS Laboratories, Inc. (Headquarters:Izunokuni-shi, Shizuoka; President and CEO: Masaki Nonaka; hereinafter referred to as"TAUNS") and GENEX, Inc. (Headquarters: Minato-ku, Tokyo; Co-CEOs: Ken Yagi andAtsushi Iida; hereinafter referred to as "GENEX") announce that TAUNS has subscribed to athird party allotment of new shares and stock acquisition rights of GENEX and that they haveentered into a strategic business alliance agreement to collaborate in the genomics businessfield.
TAUNS' mid- to long-term strategy is to expand its business into the field of chronic diseases,
as well as disease prevention and pre-symptomatic disease through the development of new
diagnostic technologies and next-generation POCT (*1).
On the other hand, GENEX is one of the few companies in Japan to provide whole-genome
DTC(*2) genetic testing services. While promoting services for individuals, including raredisease patients and general consumers, by accumulating genomic and healthcare data,
GENEX aims to apply the data to clinical trial recruitment and biomarker research withpharmaceutical and diagnostic companies in the medium to long term.
Through this capital and business alliance, the companies aim to develop new diagnostic
technologies by combining TAUNS' knowledge and data on diagnosis and testing with
GENEX's knowledge and data to be built in the genomics field.
(*1) POCT: Point of Care Testing. A test that can be performed outside of the laboratory and can beconducted at the subject's side. Test results can be provided quickly and easily.
(*2) DTC (Direct to Consumer) genetic testing: A service in which subjects provide their own specimens forgenome testing without going through a medical institution. The results of the genome analysis will be
provided later, and the patient will be notified of disease risks, etc.

Mr. Nonaka, President and CEO of TAUNS, and Mr. Yagi and Mr. Iida, Co-CEOs of GENEX,
commented on this alliance as follows.
1Message from Masaki Nonaka, President and CEO, TAUNS Laboratories, Inc.
“The genomic field is expected to expand further in the future due to a significant decrease in
sequencing costs and progress in the development of legislation on genomic medicine as anational policy. As a mid- to long-term strategy, TAUNS aims to develop new diagnostic
technologies using various test data, including genomic data, and has high expectations for
GENEX as a strategic partner with its advanced know-how in genomic analysis and knowledgeof the genomic field. As a shareholder of GENEX, we are confident that we can also increase
the company's corporate and shareholder value in the medium to long term.
Message from Ken Yagi and Atsushi Iida, Co-CEOs, GENEX, Inc.
“We are very pleased that TAUNS, a leading in vitro diagnostics company, has evaluated ourtechnology and entered into a strategic capital and business alliance with us. Our company's
mission is to utilize genomic information and bring the results back to the individual byproviding whole-genome testing services to individuals. We look forward to working withTAUNS to create new diagnostic technologies from test data and genomic data, and to thepossibility of making a broad contribution to society.”About TAUNS:TAUNS Laboratories, Inc. is one of the major companies of rapid diagnostic test kits for
infectious diseases in Japan. We manufacture in vitro diagnostic test kits and research
reagents applying various diagnostic technologies for global consumption. In the field of rapid
diagnostic test kits for infectious diseases, which are our main products, we have been widely
known for high-quality products and customer services by hospitals, clinics, research
institutes and biotech start-ups. For over 30 years since the company was established in 1987,
under the corporate philosophy of enriching lives and providing peace of mind, we havestrived to develop and improve our products. As a leading company of rapid diagnostic test
kits in Japan, we continue to advance R&D to meet the needs for clinical tests. For more
information, please visit our website at https://www.tauns.co.jp/en/.

About GENEX:
GENEX, a startup founded in 2019, accelerates the accumulation of healthcare data
represented by whole-genome information and provides whole-genome testing for individuals
and genome analysis services for hospitals as part of its contribution to the development of
the medical and healthcare industry.
2For more information about its technology and services, please visit our website athttps://genex.co.jp/en/toppage_en/.

The purpose of this release is to provide our stakeholders with the latest information related to our companies.
Although it may contain information on our products and research and development, it is intended to disclose
our management information and is not intended as promotion, advertisement, or medical advice regarding
our products.

For inquiries regarding this press release, please contact:
TAUNS Laboratories, Inc.
General Affairs DepartmentTEL：+81-558-76-8181
E-mail: kouhou@tauns.co.jp
GENEX, Inc.
TEL：+81-70-2490-8411
E-mail: support@genex.co.jp

3